



(51) International Patent Classification:

G01N 24/08 (2006.01) G01N 33/49 (2006.01)
A61B 5/055 (2006.01)

(21) International Application Number:

PCT/US2013/043343

(22) International Filing Date:

30 May 2013 (30.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/657,315	8 June 2012 (08.06.2012)	US
61/711,471	9 October 2012 (09.10.2012)	US
61/739,305	19 December 2012 (19.12.2012)	US
13/830,199	14 March 2013 (14.03.2013)	US

(71) Applicant: **LIPOSCIENCE, INC.** [US/US]; 2500 Summer Boulevard, Raleigh, North Carolina 27616 (US).

(72) Inventors: **OTVOS, James D.**; 1117 Wellstone Circle, Apex, North Carolina 27502 (US). **SHALAUROVA, Irina Y.**; 315 Ambermore Place, Cary, North Carolina 27519

(US). **BENNETT, Dennis W.**; 4242 North Morris Blvd., Shorewood, Wisconsin 53211 (US). **WOLAK-DINSMORE, Justyna E.**; 2808 Mebane Ln., Durham, North Carolina 27703 (US).

(74) Agent: **MYERS BIGEL SIBLEY & SAJOVEC, P.A.**; P.O. Box 37428, Raleigh, North Carolina 27627 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: NMR MEASUREMENTS OF GLYCA

INFLAMMATION MARKERS IN THE PLASMA NMR SPECTRUM
(N-ACETYL METHYL SIGNALS FROM GLYCOSYLATED ACUTE PHASE PROTEINS)




FIG. 1

(57) Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of "GlycA" in arbitrary units or in defined units (e.g., $\mu\text{mol/L}$) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, **Published:**

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

GW, KM, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*